The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

March 28, 2025

Study Completion Date

July 31, 2025

Conditions
Kidney Diseases
Interventions
OTHER

Glucagon

Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.

OTHER

Placebo

Placebo (0.9% NaCl).

OTHER

Glucagon and exendin 9-39

Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).

Trial Locations (1)

2400

RECRUITING

Physiological laboratory, Bispebjerg Hospital, Research Unit, Clinical Physiology / Nuclear Medicine Department, Copenhagen

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

The Augustinus Foundation, Denmark.

OTHER

collaborator

The Novo Nordic Foundation

OTHER

lead

Ali Asmar

OTHER